Takeda invests $5M in ALS drug from Cambridge startup Aquinnah Pharmaceuticals
Aquinnah's approach targets a protein called TDP-43 that has been found to accumulate in patients with neurodegenerative conditions like ALS, Alzheimer's disease and certain dementias.